<DOC>
	<DOCNO>NCT02716077</DOCNO>
	<brief_summary>Adult patient histologically proven melanoma treat pembrolizumab undergo FDG PET/CT scan early evaluation response therapy . Changes FDG uptake correlate lab pathology result .</brief_summary>
	<brief_title>Early FDG PET Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patient , least 18 year age History histologically confirm melanoma assess per medical record review . Eligible trial UPCC # 01615 , `` A Phase Ib Tissue Collection Study Pembrolizumab ( MK3475 ) Subjects Resectable Advanced Melanoma . '' Participants must inform investigational nature study provide write informed consent accordance institutional federal guideline prior studyspecific procedure . Females pregnant breastfeeding time screen eligible study . Female participant childbearing potential urine serum pregnancy test time screen visit . Inability tolerate image procedure opinion investigator treat physician . Serious unstable medical psychological condition , opinion investigator would compromise subject 's safety successful participation study . Ineligible trial UPCC # 01615 , `` A Phase Ib Tissue Collection Study Pembrolizumab ( MK3475 ) Subjects Resectable Advanced Melanoma . '' Only individual ( age 18 ) understand give inform consent eligible participate study . Individuals consider mentally disabled recruit study . All subject must able give informed consent . We use specific method assess decisional capacity . Economically disadvantaged person vulnerable undue influence , study offer compensation . All individual tell choice regard study participation way change access clinical care . This negate undue influence coercion . Children , fetuses , neonate , prisoner include research study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>